Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

MedImmune Is On The Block

April 16, 2007 | A version of this story appeared in Volume 85, Issue 16

MedImmune's directors have authorized management to find out if third parties have an interest in acquiring the Gaithersburg, Md., biotech firm at a price and on terms that would give its stockholders better value than they would receive if it continues on a stand-alone basis. As late as February, the board reaffirmed that the best way to maximize value was to aggressively implement its existing business plan. The company says its latest decision to seek buyers comes on indications of interest by unnamed major pharmaceutical companies coupled with recent expressions of stockholder dissatisfaction with its stock price performance.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.